AMPK activation modulates IL‐36‐induced inflammatory responses by regulating IκBζ expression in the skin

• Published in: British journal of pharmacology Vol. 181; no. 15; pp. 2429 - 2442
• Main Authors: Huang, Yi‐Ting, Chiu, Ling‐Ya, Lu, Po‐Hsuan, Hsiao, Pa‐Fan, Wang, Jen‐Yu, Lu, Ping‐Hsun, Wu, Nan‐Lin
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.08.2024
• Subjects: Adaptor Proteins, Signal Transducing; Aminoimidazole Carboxamide - analogs & derivatives; Aminoimidazole Carboxamide - pharmacology; AMP-activated protein kinase; AMP-Activated Protein Kinases - metabolism; AMPK; Animal models; Animals; Antimicrobial peptides; Cell activation; Cell culture; Cells, Cultured; Chemokine CCL20 - metabolism; Energy metabolism; Enzyme Activation - drug effects; Gene expression; Humans; Inflammation - drug therapy; Inflammation - metabolism; Inflammatory diseases; Interleukin-1 - metabolism; Interleukin-8 - metabolism; interleukin‐36; IκBζ; keratinocyte; Keratinocytes; Keratinocytes - drug effects; Keratinocytes - metabolism; Kinases; Leukocytes (neutrophilic); Mice; Mice, Inbred BALB C; Phosphorylation; Proteasomes; Protein expression; Protein turnover; Proteins; Psoriasis; pustular psoriasis; Ribonucleotides - pharmacology; skin; Skin - drug effects; Skin - metabolism; Skin - pathology; Skin diseases; Topical application; skin; AMPK; IκBζ; interleukin‐36; keratinocyte; pustular psoriasis

Background and Purpose The interleukin (IL)‐36 pathway is a critical player in the pathogenesis of pustular psoriasis. However, therapies targeting this pathway are limited or unaffordable (e.g. the anti‐IL‐36 receptor antibody). AMP‐activated protein kinase (AMPK), a regulator of cellular energy an...